ArticleDiabetes, obesity & metabolism2022
Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: The prospective COVAC-DM cohort study.
Article in Diabetes, obesity & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Association of Chronic Hyperglycemia and Glycemic Variability with Mortality in COVID-19: Meta-Analysis of Cohort Studies.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review.Diabetes & metabolic syndrome · 2022Pooled it
- Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review.Frontiers in immunology · 2022Pooled it
- Post-vaccination SARS-CoV-2 infections and antibody responses after BNT162b2 in patients with severe obesity: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Body composition measurement and diabetes - A new perspective on development of antibodies after SARS-CoV-2 booster vaccination.Journal of diabetes and metabolic disorders · 2025Article
- IL-10- and IL-13-Biased T Cell Responses to SARS-CoV-2 Vaccination in Diabetes.European journal of immunology · 2025Article
- COVID-19 vaccination lowers SARS-CoV-2 infection risk independent of diabetes, cancer and smoking in SHIP-COVID cohort, Northern Germany.Scientific reports · 2025Article
- The Intersection of SARS-CoV-2 and Diabetes.Microorganisms · 2025Review
- Sulfonohydrazide as a potential inhibitor of SARS-CoV-2 infection.Scientific reports · 2025Article
- Evaluation of neutralizing antibody titers against SARS-CoV-2 JN.1 omicron subvariant during pregnancy - A case series study.Heliyon · 2025Article
- COVID-19 vaccines and blood glucose control: Friend or foe?Human vaccines & immunotherapeutics · 2024Review
- Article
- Post-COVID syndrome and type 2 diabetes mellitus in Kazakhstan: clinical manifestations and vaccine efficacy.Annals of pediatric endocrinology & metabolism · 2024Article
- Article
- Immediate impacts of COVID-19 vaccination on glycemic control in type 1 diabetes mellitus: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2024Review
- New-Onset Diabetes Mellitus in COVID-19: A Scoping Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Comparative Analysis of Predictive Interstitial Glucose Level Classification Models.Sensors (Basel, Switzerland) · 2023Article
- Protection of inactivated vaccine against SARS-CoV-2 infections in patients with comorbidities: a prospective cohort study.Frontiers of medicine · 2023Article
- Anti-SARS-CoV-2 Antibody Level Is Associated with a History of COVID-19 Infection and mRNA Vaccination in Patients with Diabetes.Vaccines · 2023Article
- The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study.Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 4 institutions in 2 countries.
Funding
Abstract
aimsTo investigate the seroconversion following first and second COVID-19 vaccination in people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination and to analyse the response in comparison to individuals without diabetes. MATERIALS AND
methodsThis prospective, multicentre cohort study analysed people with type 1 and type 2 diabetes and a glycated haemoglobin level ≤58 mmol/mol (7.5%) or >58 mmol/mol (7.5%), respectively, and healthy controls. Roche's Elecsys anti-SARS-CoV-2 S immunoassay targeting the receptor-binding domain was used to quantify anti-spike protein antibodies 7 to 14 days after the first and 14 to 21 days after the second vaccination.
resultsA total of 86 healthy controls were enrolled in the study, as well as 161 participants with diabetes, of whom 150 (75 with type 1 diabetes and 75 with type 2 diabetes) were eligible for the analysis. After the first vaccination, only 52.7% of participants in the type 1 diabetes group and 48.0% of those in the type 2 diabetes group showed antibody levels above the cut-off for positivity. Antibody levels after the second vaccination were similar in participants with type 1 diabetes, participants with type 2 diabetes and healthy controls after adjusting for age, sex and multiple testing (P > 0.05). Age (r = -0.45, P < 0.001) and glomerular filtration rate (r = 0.28, P = 0.001) were significantly associated with antibody response.
conclusionsAnti-SARS-CoV-2 S receptor-binding domain antibody levels after the second vaccination were comparable in healthy controls and in participants with type 1 and type 2 diabetes, irrespective of glycaemic control. Age and renal function correlated significantly with the extent of antibody levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.